Saba Capital Management LP Trimmed Its Position in Qualcomm (QCOM) as Share Price Declined; Bridger Management Cut Position in Alnylam Pharmaceuticals (ALNY) by $4.62 Million as Market Valuation Rose

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Bridger Management Llc decreased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 8.88% based on its latest 2018Q4 regulatory filing with the SEC. Bridger Management Llc sold 64,225 shares as the company’s stock rose 8.95% with the market. The hedge fund held 658,785 shares of the health care company at the end of 2018Q4, valued at $48.03M, down from 723,010 at the end of the previous reported quarter. Bridger Management Llc who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be less bullish one the $9.72B market cap company. The stock increased 3.50% or $3.09 during the last trading session, reaching $91.43. About 531,035 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 28.65% since March 17, 2018 and is downtrending. It has underperformed by 33.02% the S&P500. Some Historical ALNY News: 03/05/2018 – ALNYLAM PHARMACEUTICALS INC – IF LUMASIRAN PHASE 3 STUDY POSITIVE, AN NDA SUBMISSION ANTICIPATED IN EARLY 2020; 03/04/2018 – ALNYLAM -PURSUANT TO DEAL, AGILENT HAS AGREED TO MANUFACTURE, SUPPLY TO CO, ACTIVE PHARMACEUTICAL INGREDIENTS REQUIRED FOR PATISIRAN FOR COMMERCIAL SALE; 20/04/2018 – Alnylam: Dicerna to Be Restricted in Its Development of Certain Therapeutics for 18 Mos to Four Years; 07/05/2018 – The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad; 23/04/2018 – ALNYLAM GETS POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN EU; 26/03/2018 – ALNYLAM GETS EMA PRIME DESIGNATION FOR ACCELERATED ASSESSMENT; 14/03/2018 – Alnylam: Data Will Demonstrate the Potential of Patisiran to Alleviate Multiple manifestations of hATTR Amyloidosis; 07/05/2018 – Medicines Co: Inclisiran Reduced Key Atherogenic Lipoproteins Back to Normal in 68% to 90% of Patient Studied; 20/04/2018 – ALNYLAM PHARMACEUTICALS – ALL OTHER SETTLEMENT TERMS ARE CONFIDENTIAL; 14/04/2018 – Alnylam flags looming FDA application for givosiran, adding another round of stellar efficacy data from early study $ALNY

Saba Capital Management Lp decreased its stake in Qualcomm Inc (QCOM) by 25.52% based on its latest 2018Q4 regulatory filing with the SEC. Saba Capital Management Lp sold 255,234 shares as the company’s stock declined 5.07% while stock markets rallied. The hedge fund held 744,766 shares of the radio and television broadcasting and communications equipment company at the end of 2018Q4, valued at $42.39 million, down from 1.00 million at the end of the previous reported quarter. Saba Capital Management Lp who had been investing in Qualcomm Inc for a number of months, seems to be less bullish one the $68.50B market cap company. The stock increased 2.17% or $1.2 during the last trading session, reaching $56.6. About 27.99 million shares traded or 81.77% up from the average. QUALCOMM Incorporated (NASDAQ:QCOM) has declined 17.21% since March 17, 2018 and is downtrending. It has underperformed by 21.58% the S&P500. Some Historical QCOM News: 09/04/2018 – Qualcomm Technologies Inc. and THX® Demonstrate End-to-End Workflow for Delivery of Next-Generation lmmersive Audio Experiences using MPEG-H for Broadcast at NAB 2018; 09/03/2018 – TREASURY’S MNUCHIN SAYS PREPARED TO USE CFIUS POWER TO PROTECT NATIONAL SECURITY IN QUALCOMM-BROADCOM REVIEW; 12/03/2018 – Trump Scuttles $117 Billion Broadcom, Qualcomm Deal (Video); 06/03/2018 – A secretive US national security committee has issued an unusual public warning against Broadcom’s proposed $142bn hostile takeover of San Diego-based Qualcomm, saying that a deal might lead to China overtaking the US in critical 5G technology; 28/05/2018 – IBT: Qualcomm To Meet China Regulators In Push To Clear $44 Billion NXP deal: Sources; 19/04/2018 – RT @CNBCnow: LATEST: Qualcomm very concerned with the fate of NXP deal as the firms extend merger agreement, refile with MOFCOM – sources h…; 25/04/2018 – QUALCOMM INC QTRLY QCT REVENUES OF $$3,897 MLN VS $3,676 MLN REPORTED LAST YEAR; 27/04/2018 – Lenders feel benefit of M&A surge; 19/03/2018 – Rep. Hunter: TRUMP ADMINISTRATION FOLLOWS HUNTER LEAD ON REVIEWING QUALCOMM DEAL; 05/03/2018 – SVbizjournal: Breaking: Qualcomm delays key shareholder vote amid federal scrutiny of Broadcom deal

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on May, 2. They expect $-2.15 earnings per share, down 52.48% or $0.74 from last year’s $-1.41 per share. After $-2.09 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 2.87% negative EPS growth.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam files application in Britain for study of RNAi hypertension candidate – Seeking Alpha” on March 11, 2019, also Seekingalpha.com with their article: “FDA OKs Novo’s Esperoct for hemophilia A – Seeking Alpha” published on February 19, 2019, Bizjournals.com published: “FDA panel says Karyopharm’s cancer drug shows ‘significant toxicity’ – Boston Business Journal” on February 25, 2019. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Nasdaq.com and their article: “Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus – Nasdaq” published on February 28, 2019 as well as Nasdaq.com‘s news article titled: “Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report? – Nasdaq” with publication date: March 09, 2019.

Investors sentiment increased to 1.07 in Q4 2018. Its up 0.01, from 1.06 in 2018Q3. It is positive, as 34 investors sold ALNY shares while 70 reduced holdings. 28 funds opened positions while 83 raised stakes. 89.04 million shares or 2.44% more from 86.92 million shares in 2018Q3 were reported. Clearbridge Invests Limited holds 0% or 377 shares. Sio Cap Mgmt Limited Liability Corp has invested 4.11% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Bridger Mngmt Ltd Company has 4% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Cls Invs Limited Com owns 1,140 shares for 0% of their portfolio. Northern Trust Corporation stated it has 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Eaton Vance Mngmt invested in 0.01% or 37,791 shares. Qs Invsts, New York-based fund reported 2,408 shares. Quantitative Mngmt Ltd Liability Corp invested in 0.07% or 19,900 shares. Huntington National Bank & Trust has 1,000 shares. Hsbc Plc, United Kingdom-based fund reported 120,080 shares. Mutual Of America Mngmt Limited, New York-based fund reported 1,935 shares. 36,887 are owned by Proshare Advsrs Ltd Liability. California-based Los Angeles Cap Mngmt And Equity Rech has invested 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Hudson Bay Cap Lp holds 55,000 shares or 0.05% of its portfolio. Asset, a Colorado-based fund reported 17,883 shares.

Bridger Management Llc, which manages about $3.11B and $1.20 billion US Long portfolio, upped its stake in Medicines Co (NASDAQ:MDCO) by 720,981 shares to 3.06 million shares, valued at $58.58 million in 2018Q4, according to the filing. It also increased its holding in Golden Entmt Inc by 381,312 shares in the quarter, for a total of 1.28M shares, and has risen its stake in Caesars Entmt Corp (NASDAQ:CZR).

Investors sentiment decreased to 0.73 in Q4 2018. Its down 0.04, from 0.77 in 2018Q3. It dropped, as 91 investors sold QCOM shares while 491 reduced holdings. 104 funds opened positions while 322 raised stakes. 1.00 billion shares or 4.55% less from 1.05 billion shares in 2018Q3 were reported. Whittier Trust Com holds 0.16% or 83,969 shares. Meiji Yasuda Life Insurance Company reported 0.2% in QUALCOMM Incorporated (NASDAQ:QCOM). Lazard Asset Mngmt Ltd Liability Company invested in 1.78M shares. Lombard Odier Asset Mngmt (Usa) Corporation invested 0.21% in QUALCOMM Incorporated (NASDAQ:QCOM). Point72 Asset Mngmt LP stated it has 3.78 million shares. Geode Cap Mgmt Ltd Liability Company has invested 0.28% in QUALCOMM Incorporated (NASDAQ:QCOM). Bokf Na has invested 0.24% in QUALCOMM Incorporated (NASDAQ:QCOM). Columbus Circle has 0.71% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 438,130 shares. Blair William And Il owns 0.09% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 209,983 shares. Bamco New York invested in 0% or 4,000 shares. Royal State Bank Of Canada stated it has 7.50M shares. Victory Cap holds 17,874 shares or 0% of its portfolio. Earnest Prtnrs Ltd Company accumulated 708 shares or 0% of the stock. Stoneridge Partners Ltd Liability Company holds 0.3% in QUALCOMM Incorporated (NASDAQ:QCOM) or 16,938 shares. Philadelphia invested 0.7% in QUALCOMM Incorporated (NASDAQ:QCOM).

Analysts await QUALCOMM Incorporated (NASDAQ:QCOM) to report earnings on April, 24. They expect $0.54 earnings per share, down 19.40% or $0.13 from last year’s $0.67 per share. QCOM’s profit will be $653.57 million for 26.20 P/E if the $0.54 EPS becomes a reality. After $1.04 actual earnings per share reported by QUALCOMM Incorporated for the previous quarter, Wall Street now forecasts -48.08% negative EPS growth.

Saba Capital Management Lp, which manages about $7.93 billion and $2.78 billion US Long portfolio, upped its stake in Credit Suisse Asset Mgmt Inc (CIK) by 229,483 shares to 287,748 shares, valued at $797,000 in 2018Q4, according to the filing. It also increased its holding in Nuveen Cr Strategies Incm Fd (JQC) by 4.15M shares in the quarter, for a total of 12.84 million shares, and has risen its stake in Avon Prods Inc (NYSE:AVP).

More notable recent QUALCOMM Incorporated (NASDAQ:QCOM) news were published by: Seekingalpha.com which released: “Qualcomm: Misunderstood Legal Ramifications And 5G Tailwinds – Seeking Alpha” on March 13, 2019, also Seekingalpha.com with their article: “Your 55 March Quarter NASDAQ Dividend Dogs By Yield, Upside And Net Gains – Seeking Alpha” published on March 07, 2019, Nasdaq.com published: “Noteworthy Monday Option Activity: QCOM, PBYI, REGN – Nasdaq” on February 25, 2019. More interesting news about QUALCOMM Incorporated (NASDAQ:QCOM) were released by: Fool.com and their article: “Qualcomm Could Help TSMC Make Up for Poor iPhone Sales – The Motley Fool” published on February 16, 2019 as well as Nasdaq.com‘s news article titled: “April 12th Options Now Available For Qualcomm (QCOM) – Nasdaq” with publication date: February 28, 2019.

QUALCOMM Incorporated (NASDAQ:QCOM) Institutional Positions Chart